A. Clinical description
A person with one or more of the following not explained by another etiology:
• Clinically compatible illness that includes one or more of the following: o Fever (measured or reported), or o Rash, or o Arthralgia, or o Conjunctivitis; • Or complication of pregnancy including one of the following:
o Fetal loss or o Fetus or neonate with congenital microcephaly, congenital intracranial calcifications, other structural brain or eye abnormalities, or other congenital central nervous system-related abnormalities including defects such as clubfoot or multiple joint contractures; • Or GBS meeting Brighton Collaboration level 1, 2, or 3 or other neurologic manifestations.
B. Laboratory criteria for diagnosis

Confirmatory:
For all locally acquired cases (including index, sporadic, and locally acquired via mosquito exposure after epidemiologic linkage or transmission in an area has been established), either of the following:
• Detection of ZIKV by culture, viral antigen, or viral RNA in serum, CSF, tissue, or other specimen (e.g., urine, whole blood, amniotic fluid, semen) by a state public health laboratory (PHL) or the Centers for Disease Control and Prevention (CDC) • Or all of the following:
o Positive enzyme immunoassay (EIA), microsphere immunofluorescence assay (MIA), or immunofluorescent assay (IF) for ZIKV IgM antibodies in serum or CSF by a PHL or CDC, and o Positive neutralizing antibody titers by plaque reduction neutralization test (PRNT) against ZIKV by a PHL or CDC, and o Negative neutralizing antibody titers by PRNT against dengue virus (DENV) (or other flaviviruses endemic to the region where exposure occurred) by a PHL or CDC.
For imported cases, either of the following:
• Detection of ZIKV by culture, viral antigen, or viral RNA in serum, CSF, tissue, or other specimen (e.g., urine, whole blood, amniotic fluid, semen)
• Or all of the following: o Positive EIA, MIA, or IF for ZIKV IgM antibodies in serum or CSF; and o Positive neutralizing antibody titers by PRNT against ZIKV; and o Negative neutralizing antibody titers by PRNT against DENV (or other flaviviruses endemic to the region where exposure occurred). • 
Comment
Cross-reaction with related flaviviruses (e.g., dengue, West Nile, yellow fever, Japanese encephalitis viruses) on serological tests is common, and results may be difficult to interpret. Due to this cross-reactivity, it is important to ask if there has been any lifetime travel to a flavivirus-endemic country or vaccination for yellow fever or Japanese encephalitis viruses. In addition, people with dengue infection often test positive for ZIKV IgM.
Due to the cross-reactivity seen among flaviviruses, individuals testing positive for both ZIKV and DENV IgM should be reported as flavivirus disease and infection (Merlin disease code=07000). PRNT is not required to meet these criteria; however, if a PRNT is performed, there should be positive neutralizing antibody titers to both ZIKV and DENV. If an individual with flavivirus results is epidemiologically linked to a confirmed or probable ZIKV or DENV case, the case should not be reported as a flavivirus case.
Clinicians should also consider testing for dengue and chikungunya fever for suspect cases of ZIKV disease if fever was reported. As testing capacity allows, all specimens meeting the requirements for ZIKV disease PCR testing at the Bureau of Public Health Laboratories (BPHL) will also be tested for dengue and chikungunya viruses if the patient reported fever. All specimens collected in the first four days of illness and meeting standard requirements for dengue and chikungunya testing will also be tested for Zika virus by PCR if travel to a ZIKV disease endemic area is reported.
Differentiating between ZIKV and DENV infections in PCR-negative patients with positive flavivirus labs • Conjunctivitis and pruritic rash are more common with ZIKV disease than dengue fever.
• Thrombocytopenia and leukopenia are more common and severe in cases of dengue fever compared to ZIKV disease.
• ZIKV is not known to cause severe syndromes that can be seen with DENV (dengue hemorrhagic fever or dengue shock syndrome). Acute and convalescent specimens from people with infections believed to be Florida-acquired should be sent to BPHL. Acute specimens from people with infections believed to be acquired outside Florida do not need to be forwarded to BPHL unless the specimen is from a pregnant woman, infant, or possible GBS case. • Or positive neutralizing antibody titers by PRNT against ZIKV in a sample collected ≥18 months after birth;
• Or both of the following: o Positive EIA or IFA for ZIKV IgM antibodies from a commercial laboratory; o And no testing performed by a PHL or CDC on the same specimen;
• Or both of the following: o Positive ZIKV PCR by a commercial laboratory; o And no testing performed by a PHL or CDC on the same specimen.
Not a case:
One or more of the following:
• Both of the following: o Positive or equivocal EIA or IFA for ZIKV IgM antibodies by a commercial laboratory; o And negative or indeterminate EIA or IFA for ZIKV IgM antibodies by a PHL or CDC for the same specimen;
• Or all of the following: o Positive ZIKV PCR by a commercial laboratory; o And negative or equivocal PCR by a PHL or CDC; o And absence of a positive or equivocal EIA or IFA for ZIKV IgM antibodies by a PHL or CDC for the same specimen;
• Or positive neutralizing antibody titers by PRNT against ZIKV in a sample collected <18 months after birth;
• Or negative neutralizing antibody titers by PRNT against ZIKV;
• Or negative ZIKV PCR;
• Or negative or indeterminate EIA or IFA for ZIKV IgM antibodies;
• Or testing is otherwise determined to be falsely positive by case reviewer.
*Note: while collection of umbilical cord blood was initially recommended, neonatal serum is the preferred specimen type. Umbilical cord blood should only be submitted for testing when no serum is available.
C. Epidemiologic Linkage Criteria
Mother One or more of the following:
• Resides in or recent travel to an area with known ZIKV transmission 
D. Case classification
Zika virus disease
Confirmed:
• Clinically compatible congenital disease in a neonate with confirmatory laboratory evidence whose mother meets the epidemiologic criteria.
Probable:
• Clinically compatible congenital disease in a neonate with presumptive laboratory evidence whose mother meets the epidemiologic criteria.
Suspect:
Either of the following:
• Clinically compatible congenital disease in a neonate with supportive laboratory evidence whose mother meets the epidemiologic criteria • Or clinically compatible congenital disease in an infant with supportive laboratory evidence and the infant epidemiologic criteria.
Zika virus infection
• A neonate with confirmatory laboratory evidence whose mother meets the epidemiologic criteria.
• A neonate with presumptive laboratory evidence whose mother meets the epidemiologic criteria.
Suspect:
Last Revised: January 8, 2019 Florida Department of Health Page 15 of 31
• A neonate with supportive laboratory evidence whose mother meets the epidemiologic criteria • Or an infant with supportive laboratory evidence and the infant epidemiologic criteria.
Comment
As part of the complete evaluation of congenital microcephaly or other CNS birth defects, testing for other congenital infections such as syphilis, toxoplasmosis, rubella, cytomegalovirus infection, lymphocytic choriomeningitis virus infection, and herpes simplex virus infections should be considered. An assessment of potential genetic and other teratogenic causes of the congenital anomalies should also be performed.
Cross-reaction with related flaviviruses (e.g., dengue, West Nile, yellow fever, Japanese encephalitis viruses) on serological tests is common and results may be difficult to interpret. Due to this cross-reactivity, it is important to ask if there has been any lifetime travel by the mother to a flavivirus-endemic country or vaccination for yellow fever or Japanese encephalitis viruses. In addition, people with dengue infection often test positive for ZIKV IgM. It is also important to get the lifetime travel history for the infant, particularly if PRNT testing is going to be performed at 18 months of age to assess congenital exposure.
Specimens from infants with possible congenital infections should be sent to the Bureau of Public Health Laboratories.
LABORATORY TESTING
A. Criteria for diagnosis
Confirming the diagnosis of ZIKV infection can be made using a variety of testing methods. BPHL provides confirmatory laboratory testing services for specimens forwarded for confirmation that meet epidemiological criteria (appropriate signs and symptoms as well as travel history).
1. ZIKV PCR positive commercial laboratory test results should be confirmed by BPHL for pregnant women, and suspected local, congenital, and GBS cases. Specimens testing positive, equivocal, or inconclusive/indeterminate for IgM antibodies should be forwarded to BPHL for repeat IgM and plaque reduction neutralization testing (PRNT), as needed. If available, specimens for non-pregnant, symptomatic travel-associated cases and Zika reactive blood donors may also be forwarded for confirmation. 2. Health care providers should collect both serum and urine specimens from patients who are symptomatic. Uninsured symptomatic individuals with two of the key symptoms reported (fever, rash, arthralgia, and conjunctivitis) or GBS and travel to an area experiencing ZIKV activity can be sent to BPHL. Specimens from individuals without travel with three of the key symptoms should be sent to BPHL. 3. Serum and urine may also be submitted for uninsured pregnant women with appropriate epidemiologic risk factors, regardless of reported symptoms. Specimens from all infants born to women who may have been exposed to ZIKV during pregnancy should also be sent. Please see below for more information on testing of pregnant women, infants, and other specimen types that may be collected for PUIs. , travel country/territory and dates, and whether fever was reported on all orders. 2. Specimen Collection a. Specimens for PCR testing should be collected within the first 14 days of illness or exposure: serum (2 mL serum/red or red/grey marble tiger top tube) AND urine specimen (1-2 mL, 5 mL max, in a sterile tube) should both be collected. Do not submit urine in urine collection cups as these tend to leak during transport. Use a sterile tube with secure closure to prevent leakage. Each tube should be in a separate zip-seal bag. Use sterile tubes for urine and seal or cap container(s) securely to avoid leakage and loss of specimen. Other specimen types such as whole blood (EDTA), CSF, and amniotic fluid may also be appropriate in consultation with the Arbovirus Surveillance Coordinator. These specimens should be submitted with a patient-matched serum specimen. b. Serum only for IgM testing is preferred if collected ≥14 days following symptom onset or exposure. PCR testing will only be performed if serological tests are positive and the patient is pregnant or has no travel. c. Specimens (serum, whole blood, and CSF only) meeting the requirements for Zika PCR testing at BPHL will also be tested for dengue and chikungunya via trioplex i. The most current CDC guidelines for testing of pregnant women are available at www.cdc.gov/mmwr/zika_reports.html. Due to the declining prevalence of ZIKV in the Americas and the possibility of prolonged IgM antibody detection, the following two groups should be tested at BPHL: uninsured symptomatic pregnant women and uninsured asymptomatic pregnant women with ongoing possible ZIKV exposure. ii. Testing at BPHL should not be approved for pregnant women without risk factors for ZIKV exposure (e.g., no travel history to areas with active transmission, no sexual contact with a partner who lives in or traveled to an area with active ZIKV infection, etc.) unless the woman meets local PUI criteria. These individuals should be counseled on the risks and benefits of testing (e.g., false positives and negatives) and reassured that testing is unnecessary. Specimens should go directly to the commercial laboratory if the woman has a private provider and insurance. iii. Unless a Zika-associated abnormality is reported in the infant, testing of pregnant women with possible ZIKV exposure should occur during pregnancy through the end of the first postnatal week. For testing and investigation purposes, a woman is considered pregnant if her possible ZIKV exposure occurred at any point during pregnancy or within two months of conception. The length of ZIKV IgM detection is unknown, but epidemiological and laboratory data indicate that it may persist for more than 12 weeks. Specimens collected after 12 weeks can still be tested; however, a negative IgM result does not definitively prove that the person wasn't exposed to Zika virus as testing may not occur soon enough for Zika IgM antibodies to still be detectable. iv. If a pregnant woman tests positive for Zika by PCR and she and her provider are interested in additional testing, coordinate with the physician to collect specimens weekly until PCR results are negative. Some research has speculated that viral replication in the placenta or fetus could be a cause of prolonged viremia. However, it is unknown how prolonged viremia can impact the fetus during pregnancy. e. FOR INFANTS ONLY: Serum should be collected from infants whose mother had travel to a country or region with ZIKV transmission at any point in pregnancy or the two months before conception or who had possible sexual exposure with a male partner that traveled in the 3 months prior to sexual intercourse. Infant testing should be expedited if the mother has not previously been tested. Specimens can be collected from both mother and infant at birth if not previously tested. i. Infant specimens should be collected within two days of birth. Please submit the requested volumes indicated above; if this is not possible a minimum
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Florida Department of Health Page 18 of 31 of 0.5 mL for each specimen type may be submitted. It is important for specimens to be clearly marked as belonging to the infant vs. the mother. If specimens are not collected within two days of birth, attempt to collect specimens at the next doctor's visit. CSF may also be collected if the infant has an abnormality and the CSF is being collected for other purposes. For infants with abnormalities consistent with congenital Zika syndrome (CZS) and potential ZIKV exposure during pregnancy, serum specimens can also be submitted once the infant is 18 months old. PRNT testing will be performed on these specimens to determine whether there was a congenital exposure for the infant. Testing will be available for infants up to 36 months of age. Please reach out to the Arbovirus Surveillance Coordinator or Pregnancy Registry Coordinator for testing approval. ii. Amniotic fluid: Based on experience with other congenital infections, amniocentesis has been used in the past to diagnose intrauterine infections. However, the performance of PCR testing of amniotic fluid for Zika virus infection has not been evaluated. i. If the specimen is acute (collected 14 or fewer days post onset), the serum or urine should be shipped frozen on dry ice in an insulated cooler. Hold specimens in an insulated container with dry ice or an ultra-low freezer until shipped. This is best for virus isolation, but viral RNA may still be detectable in freshly collected acute serum or urine that is immediately sent overnight to the laboratory with frozen gel ice in an insulated cooler. ii. If the specimen is convalescent (collected 15 or more days post onset), the serum may be shipped frozen on dry ice or cold with frozen gel ice in an insulated cooler because the serum will be tested for antibody only. Hold serum in a refrigerator until shipped. iii. Serum is stored in standard sterile airtight tubes or a serum separator tube (separated prior to refrigeration and shipping) without added media or fixative. iv. Each specimen must be labeled with the patient's name, date of birth, and date of collection. c. A DOH Clinical Laboratory Submission Form must be included for each patient, listing all specimens. Follow packaging and shipping guidelines for diagnostic Ask what information has been given to the patient, including whether the patient knows about the diagnosis and risk factors. 5. Ask if patients were advised to avoid mosquito bites while ill and to take sexual precautions. 6. Obtain as much demographic information as possible, including contact information (home, cellular, pager, and work numbers). Ask how and where the patient can be contacted (i.e., at hospital or home). 7. Notify the physician that you will be contacting the case as DOH follows up on all cases of ZIKV infection to assess risks factors, to better characterize the occurrence of these infections in Florida, and to identify potential means for preventing further transmission. It is also appropriate at this point to determine if the physician has any concerns about the health department contacting the case. 8. Request medical records for any PUIs that have inpatient hospitalizations potentially linked to ZIKV infection. Medical records should also be requested for pregnant cases and possible CZS cases. See Section 6 for more information on suggested medical record collection for infants and pregnant women. 9. The CHD designee will arrange acute and convalescent blood specimen collection and submission to BPHL, as appropriate, to confirm infection with a vector-borne disease. Specimens from suspect local cases, uninsured pregnant women, infants potentially exposed to ZIKV during pregnancy, suspect GBS cases, and individuals without health insurance should be sent to BPHL. 10. If the PUI meets the case definition for a confirmed, probable, or suspect case, the CHD is responsible for reporting all required information in Merlin under the appropriate disease code.
B. Inform local mosquito control personnel of suspected Zika case (if applicable)
1. For counties with a mosquito control district, notification should occur for the following: a. A symptomatic PUI that was in Florida any time from two days prior to symptom onset to 10 days post symptom onset. If reporting occurs more than two months after
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symptom onset, no notification to mosquito control is needed. Discuss this time frame with mosquito control to ensure they have no concerns. b. An asymptomatic PUI that has any PCR-positive lab results from a commercial or reference laboratory. If the PUI tests negative for ZIKV after confirmatory testing at BPHL, please let mosquito control know they can cease abatement efforts. 2. For counties without a mosquito control district, the County Health Officer should alert the state epidemiology office to coordinate with the Florida Department of Agriculture and Consumer Services (FDACS) regional response team if either a or b below are met. FDACS team deployment will be determined on a case-by-case basis depending on the risk for sustained local ZIKV transmission. a. A symptomatic person that meets PUI criteria with PCR-positive laboratory results from a commercial or reference laboratory. b. An asymptomatic PUI with PCR-positive lab results from a commercial or reference laboratory. If the PUI tests negative for ZIKV after confirmatory testing at BPHL, please let the FDACS regional response team know they can cease abatement efforts. 3. Provide work or other addresses as appropriate to mosquito control for PUIs that have a high risk for mosquito exposure due to occupation or other activities (i.e., primarily outdoors).
C. Interview the case 1. Contact the case or the case's proxy to complete an interview as soon as possible after being reported to optimize recall. a. Make at least three phone call attempts to reach the case. Additional tools such as LexisNexis can help to potentially identify additional ways to contact the person. If a CHD does not have access to LexisNexis and needs assistance with looking up additional contact information, please reach out to the Arbovirus Surveillance Coordinator. b. Calls should be made at different times of the day, with at least one attempt in the evening. c. If unable to reach by phone or certified letter, a field visit to the home should be made for suspected locally acquired cases. This form can be used to guide the interview and can be completed during the interview.www.floridahealth.gov/diseases-and-conditions/disease-reporting-andmanagement/disease-reporting-and-surveillance/_documents/crf-zika-confidential.pdf. 3. Items to cover during interview include:
a. Provide brief background on disease, including mode of transmission, incubation period, symptoms, etc. b. Remind patient to avoid mosquito bites while ill. considered pregnant if potentially exposed to ZIKV during pregnancy or within the two months prior to pregnancy, not necessarily if she is pregnant at the time of testing. This may be difficult to determine for pregnant women living in endemic areas. f. Collect history of blood transfusions, organ transplants, or blood donations in the past six months. g. As part of the interview, provide basic education to the cases about personal protection measures to prevent mosquito bites and the "Drain and Cover" message. Emphasize the need to drain standing water at least once a week. h. Provide basic education on the risk of sexual transmission and the importance of taking appropriate precautions. i. Arrange for additional specimens to be collected, if needed.
D. Merlin data entry
1. Create a case in Merlin under the appropriate disease code. Cases should be created for both imported and locally acquired cases. Individuals meeting case criteria should have the case survey selected on the basic case screen in Merlin. Cases should also be created for non-Florida residents who were exposed or tested in Florida.
In addition, cases should be created for PUIs. A person who is having a specimen tested for ZIKV at BPHL or CDC is considered a PUI. Counties can choose whether to enter PUIs under the case or PUI survey on the basic case screen in Merlin. The PUI survey is a shorter survey that streamlines data entry for users and is limited to key pieces of information. G. Enhanced surveillance for local cases 1. In the event of a locally acquired case of ZIKV infection, an outbreak, or an increase in the number of imported cases, alert health care providers, hospital emergency rooms, and student health centers of the potential for additional patients. 2. The Arbovirus Surveillance Coordinator will notify Florida blood banks and provide the ZIP Code(s) of likely exposure locations for a single suspect or confirmed ZIKV infection. As more detailed epidemiologic information becomes available, the ZIP Codes of concern will be adjusted accordingly. In addition, if any areas of active transmission are identified, the Department will provide those areas as well. Blood banks at a minimum will screen and defer donors as described in the OneBlood Strategy to Protect the Blood Supply From Mosquito-Borne (Arbovirus) Disease, which is available in the List of Appendices. All blood donations and some plasma donations in Florida are screened for ZIKV. Donors with positive results are reported back to the CHD for additional specimen collection and follow-up. The original donation specimen should be forwarded to BPHL for repeat testing. A second specimen may also need to be collected if testing on the original donation specimen is negative or inconclusive. 3. Encourage health care providers to consider Zika in any person(s) presenting with symptoms associated with this virus. Guidance for health care providers, including one pagers with information for obstetricians and clinicians can be found at https://zikafreefl.org/. Additional CDC guidance documents for health care providers can 
